CordenPharma and Viking Therapeutics Forge a Strategic Alliance for GLP-1 Drug Development CordenPharma has established a long-term partnership with Viking Therapeutics to support the development of GLP-1 drug VK2735. This alliance enables integrated supply solutions for peptide therapeutics.

CordenPharma and Viking Therapeutics Forge a Strategic Alliance for GLP-1 Drug Development #Viking_Therapeutics #Switzerland #GLP-1 #Basel #CordenPharma

CordenPharma and Viking Therapeutics Forge Strategic Alliance for GLP-1 Drug Supply Chain CordenPharma has partnered with Viking Therapeutics for the comprehensive supply of GLP-1 therapies. This alliance aims to enhance production and meet growing demand.

CordenPharma and Viking Therapeutics Forge Strategic Alliance for GLP-1 Drug Supply Chain #USA #Viking_Therapeutics #Basel #CordenPharma #GLP-1_Peptides

CordenPharma and Viking Therapeutics Form Strategic Alliance for GLP-1 Peptide Supply CordenPharma and Viking Therapeutics have established a long-term strategic partnership to supply innovative GLP-1 peptide therapies, enhancing patient care.

CordenPharma and Viking Therapeutics Form Strategic Alliance for GLP-1 Peptide Supply #USA #Viking_Therapeutics #GLP-1 #CordenPharma

CordenPharma and Viking Therapeutics Forge a Strategic Partnership for GLP-1 Peptide Supply CordenPharma has entered a long-term partnership with Viking Therapeutics to deliver integrated solutions for GLP-1 peptides, injectables, and oral formulations.

CordenPharma and Viking Therapeutics Forge a Strategic Partnership for GLP-1 Peptide Supply #USA #Viking_Therapeutics #Basel #CordenPharma #GLP-1_Peptides

CordenPharma and Viking Therapeutics Forge Long-Term GLP-1 Peptide Supply Partnership CordenPharma and Viking Therapeutics have entered a strategic partnership to ensure a steady supply of GLP-1 peptide products for innovative drug VK2735, highlighting advancement in therapeutic peptides.

CordenPharma and Viking Therapeutics Forge Long-Term GLP-1 Peptide Supply Partnership #USA #Viking_Therapeutics #Basel #CordenPharma #GLP-1_Peptides

Viking Therapeutics Forms Strategic Alliance With CordenPharma for VK2735 Production Viking Therapeutics has secured a multi-year agreement with CordenPharma to support the manufacturing and commercialization of its VK2735 obesity treatment, ensuring a steady supply of API and final products for market demand.

Viking Therapeutics Forms Strategic Alliance With CordenPharma for VK2735 Production #United_States #San_Diego #Viking_Therapeutics #VK2735 #CordenPharma

CordenPharma Invests Over €1 Billion to Expand Peptide Platform in Basel, Switzerland CordenPharma is making a substantial investment exceeding €1 billion to enhance its peptide manufacturing capabilities in Basel, Switzerland and beyond.

CordenPharma Invests Over €1 Billion to Expand Peptide Platform in Basel, Switzerland #Switzerland #Basel #CordenPharma #peptides

CordenPharma Invests Over 500 Million Euros in New Swiss Peptide Facility CordenPharma is set to enhance its peptide production capabilities with a major investment in a new facility in Basel, Switzerland. The project will create over 300 jobs.

CordenPharma Invests Over 500 Million Euros in New Swiss Peptide Facility #Switzerland #Basel #CordenPharma #Peptide_Production

CordenPharma Unveils Major Construction Plans for Peptide Manufacturing Facility in Switzerland CordenPharma is set to invest over €1 billion in expanding its peptide manufacturing capabilities, including a new facility in Switzerland, aiming for heightened production by 2028.

CordenPharma Unveils Major Construction Plans for Peptide Manufacturing Facility in Switzerland #Switzerland #Basel #CordenPharma #Peptide_Manufacturing

CordenPharma Boosts Peptide Manufacturing with Major Greenfield Investment in Switzerland CordenPharma is set to invest over €1 billion in peptide manufacturing growth, focusing on a new greenfield facility near Basel, Switzerland.

CordenPharma Boosts Peptide Manufacturing with Major Greenfield Investment in Switzerland #Switzerland #Basel #CordenPharma #Peptide_Manufacturing #Muttenz

CordenPharma's Strategic Investment in Peptide Manufacturing Over 1 Billion Euro Marks Significant Growth in Switzerland CordenPharma's massive investment of over 500 million euros in a new peptide manufacturing facility near Basel, Switzerland, highlights its growth plans.

CordenPharma's Strategic Investment in Peptide Manufacturing Over 1 Billion Euro Marks Significant Growth in Switzerland #Switzerland #Basel #CordenPharma #peptides

CordenPharma Unveils Over €500 Million Investment in New Peptide Facility in Switzerland CordenPharma is investing over €500 million to establish a state-of-the-art peptide facility in Basel, Switzerland, enhancing its production capabilities.

CordenPharma Unveils Over €500 Million Investment in New Peptide Facility in Switzerland #Switzerland #Basel #CordenPharma #Peptide_Manufacturing #Basel_Switzerland